Genomic Health (NASDAQ:GHDX) Downgrade
JPMorgan gave Genomic Health (NASDAQ:GHDX) shares a new “Underweight” rating in a report revealed to clients on Wednesday morning. This is downgrade from the last “Neutral” rating.
This stock rating downgrade is noticed by equity trades, as NASDAQ:GHDX is at the moment trading -2.61% lower at $32.05 as of 8:17 AM New York time. Genomic Health shares have [From2] 0% over the last 200 days, while the S&P 500 has increased 6.00% over the same time.
Baker Bros. Advisors Lp had the largest stake with ownership of 13.77 million shares as of q2 2015 for 3.61% of the US equity exposure. Camber Capital Management Llc is another very bullish investment manager who is owning 2.46 million shares of Genomic Health or 3.13% of their US equity exposure. Also, Motley Fool Asset Management Llc have 0.84% of their US equity exposure invested in the company for 131,935 shares. The Colorado-based fund Tributary Capital Management Llc disclosed it had purchased so far a stake worth about 0.83% of the investment manager’s stock portfolio in Genomic Health. The California-based fund Acuta Capital Partners Llc is also positive about the stock, possessing 221,354 shares or 0.78% of their US equity exposure.
Genomic Health (NASDAQ:GHDX) Profile
Genomic Health, Inc. is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.
Genomic Health (NASDAQ:GHDX) traded down -2.61% on 13 December, hitting $32.05. A total of 127,212 shares of the company’s stock traded hands. This is up from average of 93,312 shares. Genomic Health has a 52 week low of $23.57 and a 52 week high of $33.96. The company has a market cap of $1.07 billion and a P/E ratio of 0.
Get the latest Genomic Health (NASDAQ:GHDX) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
The post JPMorgan Reduces Genomic Health (NASDAQ:GHDX) Rating to “Underweight” from “Neutral” appeared first on Octafinance.